{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:50:35Z","timestamp":1785480635709,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>None of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25\u201350\u2009mg\/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9. Quality of life (QoL) was assessed by EQ5D questionnaire. Between-group differences (spironolactone minus control [\u0394s]) were analyzed by repeated measures ANOVA with adjustment for baseline and, if appropriate, additionally for sex, age and body mass index. \u0394s in the pre-exercise systolic\/diastolic BP were \u22128.00\u2009mm Hg (95% CI, \u221211.6 to \u22124.43)\/\u22120.85\u2009mm Hg (\u22122.96 to 1.26) at month 1 and \u22129.58\u2009mm Hg (\u221214.0 to \u22125.19)\/\u22123.84\u2009mm Hg (\u22126.22 to \u22121.47) at month 9. \u0394s in the post-exercise systolic\/diastolic BP were \u22128.08\u2009mm Hg (\u221214.2 to \u22122.01)\/\u22122.07\u2009mm Hg (\u22125.79 to 1.65) and \u221213.3\u2009mm Hg (\u221219.9 to \u22126.75)\/\u22124.62\u2009mm Hg (\u22128.07 to \u22121.17), respectively. For completed shuttles, \u0394s at months 1 and 9 were 2.15 (\u22120.10 to 4.40) and 2.49 (\u22120.79 to 5.67), respectively. \u0394s in QoL were not significant. The correlations between the exercise-induced BP increases and the number of completed shuttles were similar in both groups. In conclusion, in patients at increased risk of developing HF, spironolactone reduced the pre- and post-exercise BP, but did not improve exercise capacity or QoL.<\/jats:p>","DOI":"10.1038\/s41440-024-01843-z","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:02:44Z","timestamp":1725620564000},"page":"3225-3236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial"],"prefix":"10.1038","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4254-5215","authenticated-orcid":false,"given":"Fang-Fei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0464","authenticated-orcid":false,"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-6528","authenticated-orcid":false,"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-7050","authenticated-orcid":false,"given":"De-Wei","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-1298","authenticated-orcid":false,"given":"Job A. J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-0454","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-1799","authenticated-orcid":false,"given":"Fozia Z.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-9450","authenticated-orcid":false,"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-3873","authenticated-orcid":false,"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-7803","authenticated-orcid":false,"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Cuthbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-668X","authenticated-orcid":false,"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-5968","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3583-3593","authenticated-orcid":false,"given":"Tim S.","family":"Nawrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0079-6996","authenticated-orcid":false,"given":"Javier","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-7016","authenticated-orcid":false,"given":"John G. F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-1637","authenticated-orcid":false,"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the HOMAGE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Asayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bozec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P.","family":"Brunner La Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G. F.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Grojean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hazebroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine W.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1ia","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys E.","family":"Maestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda U.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pizard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Ravassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Staessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job A. J.","family":"Verdonschot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Fei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"1843_CR1","first-page":"1365","volume":"11","author":"P Martens","year":"2023","unstructured":"Martens P, Augusto SN, Finet JE, Tang WHW. Distinct impact of noncardiac comorbidities on exercise capacity and functional status in chronic heart failure. JACC: Heart Fail. 2023;11:1365\u201376.","journal-title":"JACC: Heart Fail"},{"key":"1843_CR2","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1097\/00004872-199917121-00030","volume":"17","author":"R Fagard","year":"1999","unstructured":"Fagard R, Pardaens K, Vanhaecke J. Prognostic significance of exercise versus resting blood pressure in patients with chronic heart failure. J Hypertens. 1999;17:1977\u201381.","journal-title":"J Hypertens"},{"key":"1843_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ejhf.1838","volume":"23","author":"S von Haehling","year":"2021","unstructured":"von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, et al. Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. Eur J Heart Fail. 2021;23:92\u2013113.","journal-title":"Eur J Heart Fail"},{"key":"1843_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.12965\/jer.2346418.209","volume":"19","author":"R Singh","year":"2023","unstructured":"Singh R, Aggarwal D, Dutta K, Jaggi S, Sodhi MK, Saini V. Assessment of the feasibility of 1-min sit-to-stand test in evaluating functional exercise capacity in interstitial lung disease patients. J Exerc Rehabil. 2023;19:363\u20139.","journal-title":"J Exerc Rehabil"},{"key":"1843_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/2047487317690951","volume":"24","author":"I Hecht","year":"2017","unstructured":"Hecht I, Arad M, Freimark D, Klempfner R. Blood pressure dynamics during exercise rehabilitation in heart failure patients. Eur J Prev Cardiol. 2017;24:818\u201324.","journal-title":"Eur J Prev Cardiol"},{"key":"1843_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1536\/ihj.51.111","volume":"51","author":"Y Nishiyama","year":"2010","unstructured":"Nishiyama Y, Morita H, Harada H, Katoh A, Adachi H, Koga A, et al. Systolic blood pressure to exercise as predictor of mortality in patients with chronic heart failure. Int Heart J. 2010;51:111\u20135.","journal-title":"Int Heart J"},{"key":"1843_CR7","doi-asserted-by":"publisher","first-page":"e019460","DOI":"10.1161\/JAHA.120.019460","volume":"10","author":"HA Carneiro","year":"2021","unstructured":"Carneiro HA, Song RJ, Lee J, Schwartz B, Vasan RS, Xanthakis V. Association of blood pressure and heart rate responses to submaximal exercise with incident heart failure: the Framingham Heart Study. J Am Heart Assoc. 2021;10:e019460.","journal-title":"J Am Heart Assoc"},{"key":"1843_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/CIR.0b013e3181e52e69","volume":"122","author":"GJ Balady","year":"2010","unstructured":"Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician\u2019s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:191\u2013225.","journal-title":"Circulation."},{"key":"1843_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(05)60821-5","volume":"352","author":"SD Keell","year":"1998","unstructured":"Keell SD, Chambers JS, Francis DP, Edwards DF, Stables RH. Shuttle-walk test to assess chronic heart failure. Lancet. 1998;352:705.","journal-title":"Lancet."},{"key":"1843_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0167-5273(00)00393-4","volume":"76","author":"FJ Morales","year":"2000","unstructured":"Morales FJ, Montemayor T, Martinez A. Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure. Int J Cardiol. 2000;76:101\u20135.","journal-title":"Int J Cardiol"},{"key":"1843_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0167-5273(00)00392-2","volume":"76","author":"DP Francis","year":"2000","unstructured":"Francis DP. Low-cost shuttle walk test for assessing exercise capacity in chronic heart failure. Int J Cardiol. 2000;76:105\u20136.","journal-title":"Int J Cardiol"},{"key":"1843_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0828-282X(08)70569-5","volume":"24","author":"C Pulz","year":"2008","unstructured":"Pulz C, Diniz RV, Alves ANF, Tebexreni AS, Carvalho AC, de Paola \u00c2AV, et al. Incremental shuttle and six-minute walking tests in the assessment of the functional capacity in chronic heart failure. Can J Cardiol. 2008;24:131\u20135.","journal-title":"Can J Cardiol"},{"key":"1843_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1378\/chest.13-2071","volume":"145","author":"VF Parreira","year":"2014","unstructured":"Parreira VF, Janaudis-Ferreira T, Evans RA, Mathur S, Goldstein RS, Brooks D. Measurement properties of the incremental shuttle walk test: a systematic review. Chest. 2014;145:1357\u201369.","journal-title":"Chest."},{"key":"1843_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"1843_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"1843_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. The Aldo-HF randomized controlled clinical trial. J Am Med Assoc. 2013;309:781\u201391.","journal-title":"J Am Med Assoc"},{"key":"1843_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","volume":"68","author":"W Kosmala","year":"2016","unstructured":"Kosmala W, Rojek M, Przewlocka-Kosmala M, Wright L, Mysiak A, Marwick TH. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:1823\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"1843_CR18","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1111\/jgs.14940","volume":"65","author":"B Upadhya","year":"2017","unstructured":"Upadhya B, Hundley WG, Brubaker PH, Morgan TM, Stewart KS, Kitzman DW. The effect of spironolactone on exercise tolerance and arterial function in older patients with HFpEF. J Am Geriatr Soc. 2017;65:2374\u201382.","journal-title":"J Am Geriatr Soc"},{"key":"1843_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"1843_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"1843_CR21","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","volume":"44","author":"M Banerjee","year":"2023","unstructured":"Banerjee M, Maisman I, Pal R, Mukhopadhyay S. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. Eur Heart J. 2023;44:3686\u201396.","journal-title":"Eur Heart J"},{"key":"1843_CR22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/ejhf.1716","volume":"22","author":"P Pellicori","year":"2020","unstructured":"Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, et al. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. Eur J Heart Fail. 2020;22:1711\u201323.","journal-title":"Eur J Heart Fail"},{"key":"1843_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42:684\u201396.","journal-title":"Eur Heart J"},{"key":"1843_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/thx.2007.081208","volume":"63","author":"SJ Singh","year":"2008","unstructured":"Singh SJ, Jones PW, Evans R, Morgan MDL. Minimum clinically improvement for the incremental shuttle walking test. Thorax. 2008;63:775\u20137.","journal-title":"Thorax."},{"key":"1843_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ejhf.2394","volume":"24","author":"S Ravassa","year":"2022","unstructured":"Ravassa S, L\u00f3pez B, Ferreira JP, Girerd N, Bozec E, Pellicori P, et al. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. Eur J Heart Fail. 2022;24:321\u201331.","journal-title":"Eur J Heart Fail"},{"key":"1843_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1843_CR27","first-page":"1086","volume":"17","author":"JS Gottdiener","year":"2004","unstructured":"Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. A report from the American Society of Echocardiography\u2019s guidelines and standard committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;17:1086\u2013119.","journal-title":"J Am Soc Echocardiogr"},{"key":"1843_CR28","unstructured":"Kleinbaum DG, Kupper LL, Nizam A, Muller KE. The correlation coefficient and straight-line regression analysis. In: applied regression analysis and other multivariate methods and over. Hampshire, UK: BOOKS\/COLE CENGAGE Learning; 2010. p. 91\u2013106."},{"key":"1843_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10557-006-8282-y","volume":"20","author":"TD Szucs","year":"2006","unstructured":"Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after mycardial infarction\u2014an analysis of the EPHESUS Study from a Swiss perspective. Cardiovasc Drugs Ther. 2006;20:193\u2013204.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1843_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","volume":"31","author":"A Struthers","year":"2008","unstructured":"Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153\u20138.","journal-title":"Clin Cardiol"},{"key":"1843_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ejhf.2428","volume":"24","author":"E Potter","year":"2022","unstructured":"Potter E, Stephenson G, Harris J, Wright L, Marwick TH. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. Eur J Heart Fail. 2022;24:620\u201330.","journal-title":"Eur J Heart Fail"},{"key":"1843_CR32","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.109.912774","volume":"121","author":"B L\u00f3pez","year":"2010","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, D\u00edez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645\u201354.","journal-title":"Circulation."},{"key":"1843_CR33","doi-asserted-by":"publisher","first-page":"e022765","DOI":"10.1161\/JAHA.121.022765","volume":"11","author":"R Huang","year":"2022","unstructured":"Huang R, Lin Y, Liu M, Xiong Z, Zhang S, Zhong X, et al. Time in target range for systolic blood pressure and cardiovascular outcomes in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2022;11:e022765.","journal-title":"J Am Heart Assoc"},{"key":"1843_CR34","first-page":"e14115","volume":"53","author":"Z Zhen","year":"2023","unstructured":"Zhen Z, Choy M, Dong B, Dong Y, Liang W, Liu C, et al. Prognostic impact of abnormal sodium burden in heart failure patients with preserved ejection fraction. Eur J Clin Invest. 2023;53:e14115.","journal-title":"Eur J Clin Invest"},{"key":"1843_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1843_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","volume":"77","author":"IE Beldhuis","year":"2021","unstructured":"Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, et al. Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol. 2021;77:1211\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1843_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ehjcvp\/pvab031","volume":"8","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Collier T, Clark AL, Mamas MA, Brunner-La Rocca HP, Heymans S, et al. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:149\u201356.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1843_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.healun.2017.04.008","volume":"36","author":"CG Billings","year":"2017","unstructured":"Billings CG, Hurdman JA, Condliffe R, Elliot CA, Smith IA, Austin M, et al. Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. J Heart Lung Transplant. 2017;36:871\u20139.","journal-title":"J Heart Lung Transplant"},{"key":"1843_CR39","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/ndt\/gfy351","volume":"34","author":"SA Greenwood","year":"2019","unstructured":"Greenwood SA, Castle E, Lindup H, Mayes J, Waite I, Grant D, et al. Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity. Nephrol Dial Transplant. 2019;34:618\u201325.","journal-title":"Nephrol Dial Transplant"},{"key":"1843_CR40","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","year":"2016","unstructured":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J."},{"key":"1843_CR41","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e895\u2013e1032.","journal-title":"Circulation."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01843-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01843-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:05:21Z","timestamp":1730765121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01843-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1843"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01843-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}